Kamada (KMDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.

1 analysts have issued 1-year target prices for Kamada's shares. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts.

Kamada's stock was trading at $4.01 on January 1st, 2023. Since then, KMDA shares have increased by 31.7% and is now trading at $5.28.
View the best growth stocks for 2023 here.

Kamada saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 13,300 shares, a drop of 68.6% from the August 15th total of 42,300 shares. Based on an average daily trading volume, of 27,900 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the company's shares are short sold.
View Kamada's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our KMDA earnings forecast.

Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to the consensus estimate of $34.18 million. Kamada had a trailing twelve-month return on equity of 7.42% and a net margin of 2.35%. During the same period last year, the company earned $0.07 EPS.

Kamada updated its FY 2023 earnings guidance on Wednesday, August, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Kamada's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.94%), Wells Fargo & Company MN (1.44%), Acadian Asset Management LLC (1.26%), Altshuler Shaham Ltd (0.67%), Bank of Montreal Can (0.11%) and Calton & Associates Inc. (0.04%).

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KMDA stock can currently be purchased for approximately $5.28.

Kamada (NASDAQ:KMDA) has a market capitalization of $236.65 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.

The company employs 380 workers across the globe.

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.